Susquehanna International Group, LLP Medicenna Therapeutics Corp. Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.28 - $0.51 $12,075 - $21,994	-43,127 Reduced 80.26%	10,605 $3,000
Q2 2023 Aug 11, 2023	BUY	$0.44 - $0.82 $23,642 - $44,060	53,732 New	53,732 $25,000
Q4 2022 Feb 14, 2023	BUY	$0.4 - $0.68 $19,396 - $32,973	48,491 New	48,491 $22,000
Q2 2022 Aug 15, 2022	SELL	$0.79 - $1.32 $16,480 - $27,536	-20,861 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.26 - $1.92 $26,284 - $40,053	20,861 New	20,861 $26,000
Q2 2021 Aug 11, 2021	SELL	$2.97 - $4.28 $82,634 - $119,082	-27,823 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$3.5 - $4.56 $97,380 - $126,872	27,823 New	27,823 $114,000

863K

Ticker MDNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,637,504
Market Cap $21.6M
Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.